SCHEMBL10102206

SCHEMBL10102206

Cc1cnc(Cl)c(OCc2ccccc2)c1C(=O)Oc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.43
P4HTM Q9NXG6 1/20 0.42
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
POLB P06746 2/20 0.40
ALKBH1 Q13686 2/20 0.39
TSHR P16473 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MCL1 Q07820 1/20 0.39
BAK1 Q16611 1/20 0.39
MAOB P27338 2/20 0.39
GLRA1 P23415 1/20 0.38
PTGER1 P34995 1/20 0.38
PTGER4 P35408 1/20 0.38
PTGER3 P43115 1/20 0.38
PTGER2 P43116 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10107515 0.84 LMNA (0.44) LMNAPOLBTSHRMAPT
SCHEMBL10102212 0.81 PTPN1 (0.42) PTPN1LMNAHPGDPOLBMAPT
SCHEMBL10101770 0.81 MAPT (0.42) PTPN1P4HTMPOLBALKBH1TSHR
SCHEMBL10101768 0.78 PTPN1 (0.41) PTPN1LMNAHPGDPOLBTSHR
SCHEMBL112286 0.78 P4HTM (0.44) PTPN1P4HTMALKBH1TSHRMAPT
SCHEMBL6125199 0.74 PTPN1 (0.47) PTPN1LMNAHPGDMAOBGLRA1
SCHEMBL8804051 0.74 MRGPRX4 (0.55) PTPN1LMNAHPGDMAOBGLRA1
SCHEMBL12108741 0.74 PTPN1 (0.42) PTPN1LMNAHPGDPOLBMAPT
SCHEMBL12108742 0.74 PTPN1 (0.42) PTPN1LMNAHPGDPOLBTSHR
SCHEMBL9283029 0.74 KDM4E (0.46) PTPN1LMNAHPGDMAPTMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828988-B2 8-AZA tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2014-09-09 US disclosed
US-8367654-B2 8-AZA tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20120108569-A1 8-AZA Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108569-A1 8-AZA Tetracycline Compounds TET1, TET3, HDAC8 PTPN1 508/4885P4HTM 3624/4885LMNA 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.